EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease

Silvia Pérez-Silanes iD, Eva Martisova, Esther Moreno, Maite Solas iD, Daniel Plano iD, Carmen Sanmartin iD, María Javier Ramírez iD

International Journal of Molecular Sciences · 08.01.2024 · 25 (2) · 799

DOI: 10.3390/ijms25020799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.01.2024. Verfasst von Silvia Pérez-Silanes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Universidad de Navarra, Irunlarrea 1, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Piperidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a complex and multifactorial neurodegenerative disorder characterized by cognitive decline, memory loss, behavioral changes, and other neurological symptoms. Considering the urgent need for new AD therapeutics, in the present study we designed, synthesized, and evaluated multitarget compounds structurally inspired by sulfonylureas and pitolisant with the aim of obtaining multitarget ligands for AD treatment. Due to the diversity of chemical scaffolds, a novel strategy has been adopted by merging into one structure moieties displaying H3R antagonism and acetylcholinesterase inhibition. Eight compounds, selected by their binding activity on H3R, showed a moderate ability to inhibit acetylcholinesterase activity in vitro, and two of the compounds (derivatives 2 and 7) were also capable of increasing acetylcholine release in vitro. Among the tested compounds, derivative 2 was identified and selected for further in vivo studies. Compound 2 was able to reverse scopolamine-induced cognitive deficits with results comparable to those of galantamine, a drug used in clinics for treating AD. In addition to its efficacy, this compound showed moderate BBB permeation in vitro. Altogether, these results point out that the fragment-like character of compound 2 leads to an optimal starting point for a plausible medicinal chemistry approach for this novel strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePiperidinesHumansAcetylcholinesteraseGalantamineAcetylcholine

Stichwörter der Autor:innen

Alzheimer diseaseacetylcholine releaseblood brain barrier permeabilitynovel object recognition testpitolisant-derived sulfonylureas

Substanzen

pitolisantAcetylcholinesteraseGalantamineAcetylcholinePiperidines

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Universidad de Navarra, Irunlarrea 1, 31008 Pamplona, Spain.

ORCID-Profile: Silvia Pérez-Silanes, Maite Solas, Daniel Plano, Carmen Sanmartin, María Javier Ramírez

Zitieren

APA

Pérez-Silanes, S., Martisova, E., Moreno, E., Solas, M., Plano, D., Sanmartin, C., & Ramírez, M. J. (2024). Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease. International Journal of Molecular Sciences, 25(2), 799. https://doi.org/10.3390/ijms25020799

Vancouver

Pérez-Silanes S, Martisova E, Moreno E, Solas M, Plano D, Sanmartin C, et al. Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease. International Journal of Molecular Sciences. 2024;25(2):799. doi:10.3390/ijms25020799

BibTeX
@article{PrezSilanes2024,
  author = {Pérez-Silanes, Silvia and Martisova, Eva and Moreno, Esther and Solas, Maite and Plano, Daniel and Sanmartin, Carmen and Ramírez, María Javier},
  title = {Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {799},
  doi = {10.3390/ijms25020799}
}
Kostenlos starten →